The trial did not achieve its primary endpoint of demonstrating non-inferiority on weight loss for CagriSema compared to tirzepatide after 84 weeks, reads a Novo Nordisk press release
It empowers you to regain control over your appetite and make sustainable dietary choices, promoting long-term weight loss
Wegovy, which uses semaglutide for chronic weight management, reports alopecia (hair loss) in its product labeling at low rates from clinical trials, often around 3-5% across doses , compared to about 1% in placebo groups
It's not clear if the participants followed diet and exercise recommendations
Visit our media relations page to view contact information for public relations personnel
Attention: non recommand pour les enfants, les femmes enceintes et allaitantes